COX2/Cyclooxygenase 2 Recombinant Antibody

$Lane 1: A549 Cells; Lane 2:THP-1 Cells; Probed with COX2\/Cyclooxygenase 2 (14D5) Monoclonal Antibody (bsm-52502R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C$

Lane 1: A549 Cells; Lane 2:THP-1 Cells; Probed with COX2\/Cyclooxygenase 2 (14D5) Monoclonal Antibody (bsm-52502R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C

$IF(ICC) staining with COX2\/Cyclooxygenase 2 (14D5) Monoclonal Antibody (bsm-52502R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with COX2\/Cyclooxygenase 2 (14D5) Monoclonal Antibody (bsm-52502R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed, paraffin embedded Human lung cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with COX2\/Cyclooxygenase 2 (14D5) Monoclonal Antibody, Unconjugated (bsm-52502R) at 1:200 overnight at 4\u00b0C, DAB staining.$

Paraformaldehyde-fixed, paraffin embedded Human lung cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with COX2\/Cyclooxygenase 2 (14D5) Monoclonal Antibody, Unconjugated (bsm-52502R) at 1:200 overnight at 4\u00b0C, DAB staining.

$Paraformaldehyde-fixed, paraffin embedded Human esophageal carcinoma; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with COX2\/Cyclooxygenase 2 (14D5) Monoclonal Antibody, Unconjugated (bsm-52502R) at 1:200 overnight at 4\u00b0C, DAB staining.$

Paraformaldehyde-fixed, paraffin embedded Human esophageal carcinoma; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with COX2\/Cyclooxygenase 2 (14D5) Monoclonal Antibody, Unconjugated (bsm-52502R) at 1:200 overnight at 4\u00b0C, DAB staining.

Applications

WB
IF(ICC)

Reactivity

Human
Mouse

Overview
Catalog #	bsm-52502r-100ul
Product Name	COX2/Cyclooxygenase 2 Recombinant Antibody
Applications	WB, IF(ICC)
Reactivity	Human, Mouse
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Human COX2/ Cyclooxygenase 2 between 50 to 200 amino acids
Clonality	Recombinant
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
Target
Swiss Prot	P35354
Synonyms	Prostaglandin G/H synthase 2, Cyclooxygenase-2, PHS II, Prostaglandin H2 synthase 2, Prostaglandin-endoperoxide synthase 2, COX-2, PGH synthase 2, PGHS-2, PTGS2
Background	Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis.
Application Dilution
WB	1:300-5000
IF(ICC)	1:50-200